Podcasts about Variant

A new flu virus variant called subclade K is spreading in Japan, a survey by the Japan Institute for Health Security has found.

This week, we went live with Alana Levin from Variant Fund to discuss Variant's 2025 Crypto Trends Report, regulatory progress, stablecoin proliferation, DEX growth, wallet UX evolution, the future of global digital currencies, and more. Thanks for tuning in! As always, remember this podcast is for informational purposes only, and any views expressed by anyone on the show are solely their opinions, not financial advice. -- Resources The 2025 Crypto Trends Report: https://x.com/AlanaDLevin/status/1990804860027965727?s=20 -- Follow Blockworks Research: https://x.com/blockworksres Follow Variant Fund: https://x.com/variantfund Follow Alana: https://x.com/AlanaDLevin Follow Danny: https://x.com/defi_kay_ Follow Boccaccio: https://x.com/salveboccaccio -- Katana directs chain revenue back to DeFi users for consistently higher yields. It starts with VaultBridge, which turns bridged assets into yield streams that back a perpetually funded real yield, boosting rewards for DeFi users. Katana is pioneering Productive TVL, assets actually being used in DeFi and reinforces this with Chain-owned Liquidity, permanent liquidity the chain controls. Stop sleeping on your bags: https://app.katana.network/?utm_source=BW-Pod -- Uniswap's Trading API offers plug-and-play access to deep onchain and off-chain liquidity, delivering enterprise-grade crypto trading without the complexity - from one of the most trusted teams in DeFi.  Click to get started with seamless, scalable access to Uniswap's powerful onchain trading infrastructure. https://hub.uniswap.org/?utm_source=blockworks&utm_medium=podcast&utm_campaign=ww_web_bw_awa_trading-api_20251117_podcast_clicks -- Subscribe on YouTube: https://bit.ly/3foDS38 Subscribe on Apple: https://apple.co/3SNhUEt Subscribe on Spotify: https://spoti.fi/3NlP1hA Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ -- Timestamps: (0:00) Introduction (2:11) Market Outlook (8:31) The 2025 Crypto Trends Report (12:42) Overview of Variant Fund (15:35) Katana Ad (16:05) Potential Regulatory Risk (18:14) Crypto's Top Assets (22:24) New Crypto Assets (24:40) DEX Market Share Growth (31:14) Katana Ad (31:46) Improving Wallet UX (35:47) Stablecoin Fragmentation (46:28) Uniswap Ad (47:14) Productizing Stablecoins (52:57) Stablecoins Impact on USD Dominance (58:27) Closing Comments -- Check out Blockworks Research today! Research, data, governance, tokenomics, and models – now, all in one place Blockworks Research: https://www.blockworksresearch.com/ Free Daily Newsletter: https://blockworks.co/newsletter -- Disclaimer: Nothing said on 0xResearch is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Boccaccio, Danny, and our guests may hold positions in the companies, funds, or projects discussed.

Zack, Dave, and Charlotte talk about what we’d most like to see from Hickman’s career in the future, and bemoan our favorite tv shows cancelled too soon. Up Next: My Marvelous Year — 2012 pt. 10 X-Men Legacy #1 to #3 Marvel NOW sample platter FF #1 to #2 Avengers #1 to #3 Punisher Max […] The post My Marvelous Year 2012 Variant E: Worst TV Show Endings, and Jonathan Hickman’s Future Plans appeared first on Comic Book Herald.

It's a season finale! It's time to rank The Life of a Showgirl for real this time, none of this 'listen once and rank it', we have studied, we have debated, and now, these are our final rankings. Hosted on Acast. See acast.com/privacy for more information.

Tři návrhy na mír na Ukrajině v rozmezí necelého týdne – po úvodním americkém plánu a evropském protinávrhu se teď objevil další seznam podmínek pro ukončení bojů. Vypracovaly ho Spojené státy spolu s Ukrajinou a zástupci evropských zemí na jednání ve Švýcarsku. „Je absolutně nelogické, že má Ukrajina redukovat ozbrojené síly a Rusko si je má ponechat v aktuální velikosti. Mělo by to být opačně,“ kritizuje Macko dosavadní výsledky vyjednávání.Všechny díly podcastu Speciál Radiožurnálu můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Dr. Jim Adams, Chief Medical Officer at Northwestern Medicine, joins Lisa Dent to discuss various health topics: A new heart disease calculator that gives a thirty-year risk factor, a flu variant from Japan, and hand foot and mouth disease on the rise

Prezident Petr Pavel nadále jedná s Andrejem Babišem o jeho střetu zájmů. Více než měsíc po volbách stále není jasné, jak Babiš veřejnosti svůj střet zájmů vysvětlí, jak po něm požaduje Pavel. „Indicie zatím naznačují, že se chystá nějaké nové řešení jako například slepý svěřenský fond,“ říká v rozhovoru s Tomášem Pancířem ústavní právník Ondřej Preuss.Všechny díly podcastu Dvacet minut Radiožurnálu můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Firas is joined by Northern Variant for an in-depth conversation on how we can fix Britain what's gone wrong, what needs to change, and what the future could look like if we get it right.

This is it, the final track-by-track before we finally figure out our final rankings.So could any of these be our faves? Not long until we find out! Hosted on Acast. See acast.com/privacy for more information.

This week, one of the audio editing tools we use suggested a synopsis to me that said this episode was about the liberation that freeform jazz provides... WHAT? My garauntee to you is that our episode descriptions will remain written by the same idiots talking on the podcast. In this episode we talk about eating habits, James Gunn movie updates, Felix Variants, and the DC/Marvel digital crossovers! Our comics are TMNT v Godzilla, Youngblood, American Caper, & Thor/Shazam!

The League discusses the 1933 classic The Invisible Man. They reflect on a recent live recording session they did in front of a live audience, celebrating Clay's birthday. They delve into the movie's plot, starring Claude Rains as the Invisible Man, who uses his newfound invisibility powers to create chaos and hilarity. The hosts discuss the innovative special effects used in the film, like dealing with invisibility in 1933 and some goofy scenes involving naked bike rides. They also debate the film's campy versus serious tones, its comedic moments, and make humorous observations about the invisible man's digestive system. The episode wraps up with the trio giving the film high marks for its groundbreaking effects and fun factor. 00:00 Dramatic Opening: A Mysterious Encounter 00:41 Podcast Introduction and Live Show Recap 06:34 Universal Horror Series: Past Episodes 07:53 The Invisible Man: Movie Background and Production09:39 Claude Rains: The Man Behind the Invisible Man16:49 The Invisible Man: Plot and Key Scenes41:51 Discussing the Invisible Man's Car and Kemp's Betrayal42:50 Griffin's Encounter with Flora and His Ambitions43:50 The Police's Plan and Griffin's Antics45:39 Kemp's Fear and Griffin's Threat46:29 Griffin's Chaotic Rampage49:18 The Police's Final Plan and Griffin's Capture51:36 Griffin's Demise and Final Thoughts57:33 Reflecting on the Movie's Impact and Legacy01:01:49 Grading the Movie and Final Remarks

-Get All Episodes Ad-Free Plus Exclusive & Early Access To Episodes On https://www.patreon.com/GeekVerse-When You Subscribe To Our Patreon You Help Us Grow The Podcast and Create New Content Guest On Shows, Pick Films For Us To Review, Send Topics & More!-GeekVerse.ca is where you can find all the info on the show and where you can find it! -Come Chat With The Hosts, Join Our Discord! https://discord.gg/R5dY4CwTBecome a supporter of this podcast: https://www.spreaker.com/podcast/geekverse-podcast--4201268/support.

Welcome to episode 13 of season 3, and it could be one of our longest breakdowns of tracks ever, especially as it appears we have a lot to say about 2 of these songs... Hosted on Acast. See acast.com/privacy for more information.

Audi has returned the potent 2.0-litre turbo all-wheel drive edition of its A3 hatchback and sedan to its 2026 line-up. Not offered with the release of the 2025 A3 line-up earlier this year and previously known as the 40 TFSI, the A3 TFSI quattro 150kW S line will sell for $62,800 plus on-road costs. Available in Sportback or Sedan this all-wheel drive A3 matches a 2.0-litre turbo petrol engine with a seven-speed dual clutch automatic transmission. Power output has increased by 10kW – Audi quoting a 0-100km/hour time of 6.3 seconds. All A3 grades now gain traffic sign recognition, an updated emergency braking system with intersection detection, and an improved automated parking system. The Audi A3 remains our best selling premium small car, selling 1547 examples to the end of September, outselling the Mercedes-Benz A-Class and BMW 1 Series.See omnystudio.com/listener for privacy information.

On this episode of THE GEEK BUDDIES, John Rocha and Michael Vogel discuss the rumors that Doctor Doom is a Tony Stark variant or if Tony Stark was a Doom variant. They also discuss The Mummy franchise returning with Brendan Fraser and Rachel Weisz, a Miss Piggy movie in development with Jennifer Lawrence and Emma Stone producing and Cole Escola writing it and the Variety article of Paramount's David Ellison highlighting his approach to rebooting Star Trek from scratch. Remember to Like and Share this episode on your social media and to Subscribe to The Outlaw Nation YouTube channel below. #marvel #avengers #startrek #disney #MCU #tonystark #robertdowneyjr #thegeekbuddies ____________________________________________________________________________________ Chapters: 0:00 Intro and Rundown 1:55 The Mummy Franchise Returning with Brendan Fraser and Rachel Weisz 12:32 Jennifer Lawrence and Emma Stone Teaming Up for Miss Piggy Movie 20:21 Paramount Rebooting Star Trek Completely 34:22 Is Doctor Doom a Tony Stark Variant or Was Tony Stark a Doom Variant FOLLOW THE GEEK BUDDIES: Twitter: https://twitter.com/Geek_Buddies Follow John Rocha: https://twitter.com/TheRochaSays​​​​​ Follow Michael Vogel: https://twitter.com/mktoon Follow Shannon McClung: https://twitter.com/Shannon_McClung Instagram: https://www.instagram.com/the_geek_bu... Learn more about your ad choices. Visit megaphone.fm/adchoices

Dave and Zack have a wide-ranging discussion about the best Spider-Man stories, sports podcasts, beat-em-up arcade games, the joys of powerwashing, and Zack’s gamer shame. Up Next: My Marvelous Year — 2012 pt. 8 Amazing Spider-Man #682 to #687, #698-#700 Ends of the Earth, big ol’ milestone Venom #16 to #22 Remender run on the […] The post My Marvelous Year 2012 Variant D: Best Spider-Man stories & Gamer Shame appeared first on Comic Book Herald.

Welcome to Variant 2, and as you can tell from the length of the episode, we have had many thoughts about these three tracks.But don't skip anything, it's all VERY important. Hosted on Acast. See acast.com/privacy for more information.

Oh, hey.Did you know Taylor Swift released a new song? Didn't think so.Well, she has! So, it's time to begin our long journey through every single song and deeply analyse every single little bit.We begin with Fate of Ophelia, Elizabeth Taylor & Opalite!See ya next week x Hosted on Acast. See acast.com/privacy for more information.

Before you build slides, get crystal clear on who you're speaking to and why you're speaking at all. From internal All-Hands to industry chambers and benkyōkai study groups in Japan, the purpose drives the structure, the tone, and the proof you choose.  What's the real purpose of a business presentation? Your presentation exists to create a specific outcome for a specific audience—choose the outcome first. Whether you need to inform, convince, persuade to action, or entertain enough to keep attention, the purpose becomes your design brief. In 2025's attention-scarce workplace—Tokyo to Sydney to New York—audiences bring "Era of Cynicism" energy, so clarity of intent is non-negotiable. Choose the one primary verb your talk must deliver (inform/convince/persuade/entertain) and align evidence, tone, and timing to that verb for executives, SMEs, and multinationals alike. Use decision criteria (see checklist below) before you touch PowerPoint or Keynote.  Do now: Write "The purpose of this talk is to ___ for ___ by ___." Tape it above your keyboard. How do I define my audience before I write a single slide? Profile the room first; the content follows. Map role seniority (board/C-suite vs. managers), cultural context (Japan vs. US/Europe norms), and decision horizon (today vs. next quarter). In Japan, executives prefer evidence chains and respect for hierarchy; in US tech startups, crisp bottom lines and next steps often win. For internal Town Halls, keep jargon minimal and tie metrics to team impact; for external industry forums, cite research, case studies, and trend lines from recognisable entities (Dale Carnegie, Toyota, Rakuten). Once you know the level, you can calibrate depth, vocabulary, and the "so what" that matters to them. Skip this step and you'll either drown them in detail or sound vague.  Do now: Write three bullets: "They care about…," "They already know…," "They must decide…". Inform, convince, persuade, or entertain—how do I choose? Pick one dominant mode and let the others support it. Inform for internal/industry updates rich in stats, expert opinion, and research (think "Top Five Trends 2025" with case studies). Limit the "data dump"—gold in the main talk, silver/bronze in Q&A. Convince/Impress when credibility is on the line; your delivery quality now represents the whole organisation. Persuade/Inspire when behaviour must change—leaders need this most. Entertain doesn't mean stand-up; it means energy, story beats, and occasional humour you've tested. Across APAC, Europe, and the US, the balance shifts by culture and sector (B2B vs. consumer), but the discipline—one primary purpose—does not.  Do now: Circle the mode that matches your outcome; design every section to serve it. How do I stop the "data dump" and choose the right evidence? Curate like a prosecutor: fewer exhibits, stronger case. Open with a bold answer, then prove it with 2–3 high-leverage data points (trend, benchmark, case). Anchor time ("post-pandemic," "as of 2025") and entities (Nikkei index moves, METI guidance, EU AI Act, industry frameworks) to help AI search and humans connect dots. Keep detailed tables for the appendix or Q&A; in the main flow, show only what advances your single purpose. This approach works for multinationals reporting quarterly KPIs and for SMEs pitching a new budget. Variant phrases (metrics, numbers, stats, proof, evidence) boost retrievability without breaking flow.  Do now: Delete one slide for every two you keep—then rehearse the proof path out loud. How do leaders actually inspire action in 2025? Pair delivery excellence with relevance—then make the ask unmistakable. Inspiration is practical when urgency, consequence, and agency meet. Churchill's seven-word charge—"Never, ever ever ever ever give up"—worked because context (1941 Europe), clarity, and cadence aligned; your 2025 equivalent might be "Ship it safely this sprint" or "Call every lapsed client this week." In Japan's post-2023 labour reforms, tie actions to work-style realities; in US/Europe, link to quarterly OKRs and risk controls. Leaders at firms like Toyota and Rakuten model the ask, specify the first step, and remove friction. Finish with a one-page action checklist and a deadline.  Do now: State the concrete next action, owner, and timebox—then say it again at the close. What's the right design order—openings first or last? Design the closes first (Close #1 and Close #2), build the body, then craft the opening last. The close is the destination; design it before you chart the route. Create two closes: the "time-rich" version and a "compressed" version in case you run short. Build the body to earn those closes with evidence and examples. Only then write your opening—short, audience-hooked, and purpose-aligned. This reverse-engineering avoids rambling intros and ensures your opener previews exactly what you'll deliver. It's a proven workflow for internal All-Hands, marketing spend reviews, and external keynotes alike.  Do now: Write Close #1 and Close #2 in full sentences before touching the first slide. How do I structure my content for AI-driven search engines (SGE, Perplexity, ChatGPT, Copilot)? Lead with answer-first headings, dense entities, and time anchors in each section. Use conversational query subheads ("How do I…?"), open with a bold one-to-two-sentence answer, then a tight paragraph with comparisons (Japan vs. US/Europe), sectors (B2B vs. consumer), and named organisations. End with a mini-summary or "Do now." Keep sections 120–150 words. Add synonyms (metrics/numbers/KPIs) and timeframe tags ("as of 2025"). This GEO pattern boosts retrievability while staying human. Use it for transcripts, blogs, and Do now: Convert your next talk into six answer-first sections using this exact template. Quick checklist (decision criteria) Audience level, culture, and decision horizon defined Single dominant purpose chosen Gold evidence only in-flow; silver/bronze parked for Q&A Two closes drafted; opening written last Clear call-to-action with owner + deadline Conclusion Choose your purpose, curate your proof, and architect your flow backwards from the close. Do that, and you'll inform, convince, and—when needed—inspire action, whether you're presenting in Tokyo, Sydney, or Seattle.    Dr. Greg Story, Ph.D. in Japanese Decision-Making, is President of Dale Carnegie Tokyo Training and Adjunct Professor at Griffith University. He is a two-time winner of the Dale Carnegie "One Carnegie Award" (2018, 2021) and recipient of the Griffith University Business School Outstanding Alumnus Award (2012). A Dale Carnegie Master Trainer, Greg delivers globally across leadership, communication, sales, and presentation programs. He is the author of best-sellers Japan Business Mastery, Japan Sales Mastery, and Japan Presentations Mastery, plus Japan Leadership Mastery and How to Stop Wasting Money on Training; Japanese editions include ザ営業, プレゼンの達人, and 現代版「人を動かす」リーダー. He publishes daily insights and hosts multiple podcasts and YouTube shows for executives succeeding in Japan. 

webctrl.cgi/Blue Angel Software Suite Exploit Attempts. Maybe CVE-2025-34033 Variant? Our honeypots detected attacks that appear to exploit CVE-2025-34033 or a similar vulnerability in the Blue Angle Software Suite. https://isc.sans.edu/diary/webctrlcgiBlue+Angel+Software+Suite+Exploit+Attempts+Maybe+CVE202534033+Variant/32410 Oracle Critical Patch Update Oracle released its quarterly critical patch update. The update includes patches for 374 vulnerabilities across all of Oracle s products. There are nine more patches for Oracle s e-Business Suite. https://www.oracle.com/security-alerts/cpuoct2025.html#AppendixEBS Rust TAR Library Vulnerability A vulnerability in the popular, but no longer maintained, async-tar vulnerability could lead to arbitrary code execution https://edera.dev/stories/tarmageddon

Limb-girdle muscular dystrophies (LGMDs) encompass a group of genetically heterogeneous skeletal muscle disorders. There has been an explosion of newly identified LGMD subtypes in the past decade, and results from preclinical studies and early-stage clinical trials of genetic therapies are promising for future disease-specific treatments. In this episode, Gordon Smith, MD, FAAN, speaks with Teerin Liewluck, MD, FAAN, FANA, author of the article “Limb-Girdle Muscular Dystrophies” in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Liewluck is a professor of neurology at the Division of Neuromuscular Medicine and Muscle Pathology Laboratory at Mayo Clinic College of Medicine in Rochester, Minnesota. Additional Resources Read the article: Limb-Girdle Muscular Dystrophies Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Guest: @TLiewluck Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Smith: This is Dr Gordon Smith with Continuum Audio. Today I'm interviewing Dr Teerin Liewluck, a good friend of mine at the Mayo Clinic, about his article on the limb girdle muscular dystrophies. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders, a topic that is near and dear to my heart. Teerin, welcome to the podcast, and maybe you can introduce yourself to our listeners. Dr Liewluck: Thank you very much, Gordon, and I want to say hi to all the Continuum fans. So, I'm Dr Teerin Liewluck, I'm the professor of neurology at Mayo Clinic in Rochester, Minnesota. So, my practice focus on all aspects of muscle diseases, both acquired and genetic myopathies. Glad to be here. Dr Smith: I just had the great pleasure of seeing you at a seminar in Houston where you talked about this topic. And so, I'm really primed for this conversation, which I'm very excited about. I find this topic a little hard, and I'm hoping I can learn more from you. And I wonder if, as we get started, recognizing many of our listeners are not in practices focused purely on muscle disease, maybe you can provide some context about why this is important for folks doing general neurology or even general neuromuscular medicine? Why do they need to know about this? Dr Liewluck: Yes, certainly. So, I would say limb girdle muscular dystrophy probably the most complex category of subgroup of muscle diseases because, by itself, it includes thirty-four different subtypes, and the number's still expanding. So, each subtype is very rare. But if you group together, it really have significant number of patients, and these patients present with proximal weakness, very high CK, and these are common patients that can show up in the neurology clinic. So, I think it's very important even for general neurologists to pick up what subtle clues that may lead to the diagnosis because if we are able to provide correct diagnosis for the patients, that's very important for patient management. Dr Smith: So, I wonder if maybe we can talk a little bit about the phenotype, Terran. I mean, your article does a great job of going over the great diversity. And you know, I think many of us here, you know, limb girdle muscular dystrophy and we think of limb girdle weakness, but the phenotypic spectrum is bananas, right? Rhabdomyolysis, limb girdle distal myopathy. I mean, when should our listeners suspect LGMD? Dr Liewluck: Yes, I think by the definition to all the LGMD patients will have limb girdle of proximal weakness and very high CK. So, these are common phenotypes among thirty-four different subtypes. But if it did take into details, they have some subtle differences. In the article, what I try to simplify all these different subtypes that we can categorize at least half of them into three main group that each group the underlying defect sharing among those subtypes and also translate into similar muscles and extra muscular manifestations. You will learn that some of the limb girdle muscular dystrophy may present with rhabdomyolysis. And we typically think of this as metabolic myopathies. But if you have a rhabdomyolysis patient, the CK remain elevated even after the acute episode, that's the key that we need to think this could be LGMD. That's for an example. Dr Smith: So, I wonder if maybe we can start there. I was going to go in a different direction, but this is a good transition. It's easy to see the opportunity to get confused between LGMD or, in that case, a metabolic myopathy or other acquired myopathies. And I think particularly adult neurologists are more accustomed to seeing acquired muscle disease. Are there particular clues that, or pearls that adult neurologists seeing patients with muscle disease can use to recognize when they should be thinking about LGMD given the diverse phenotype? Dr Liewluck: Yes. What I always tell the patient is that there are more than a hundred different types of muscle diseases, but we can easily divide into groups: acquired and genetic or hereditary. So, the acquired disease is when you encounter the patients who present with acute or subacute cause of the weakness, relatively rapidly progressive. But on the opposite, if you encounter the patient who present with a much more slowly progressive cause of weakness over several months or years, you may need to think about genetic disease of the muscle with also including limb-girdle muscular dystrophy. The detailed exam to be able to distinguish between each type of muscular dystrophy. For example, if proximal weakness, certainly limb girdle muscular dystrophy. If a patient has facial weakness, scapular winking, so you would think about facial scapular hematoma dystrophy. So, the slowly progressive cause of weakness, proximal pattern of weakness, CK elevation, should be the point when you think about LGMD. Dr Smith: So, I have a question about diagnostic evaluation. I had a meeting with one of my colleagues, Qihua Fan, who's a great peripheral nerve expert, who also does neuromuscular pathology. And we were talking about how the pathology field has changed so much over the last ten years, and we're doing obviously fewer muscle biopsies. Our way of diagnosing them has changed a lot with the evolution of genetic testing. What's your diagnostic approach? Do you go right to genetic testing? Do you do targeted testing based on phenotype? What words of wisdom do you have there? Dr Liewluck: Yes, so, I mean, being a muscle pathologist myself, it is fair to say that the utility of muscle biopsies when you encounter a patient with suspects that limb girdle muscular dystrophy have reduced over the year. For example, we used to have like fifteen, seventeen hundred muscle biopsies a year; now we do only thirteen hundred biopsies a year. Yes, as you pointed out, the first step in my practice if I suspect LGMD is to go with genetic testing. And I would prefer the last gene panel that not only include the LGMD, but also include all other genetic muscle disease as well as the conjunctive myopic syndrome, because the phenotype can be somehow difficult to distinguish in certain patients. Dr Smith: So, do you ever get a muscle biopsy, Teerin? I mean you obviously do; only thirteen hundred. Holy cow, that's a lot. So, let me reframe my question. When do you get a muscle biopsy in these patients? Dr Liewluck: Muscle biopsy still is present in LGMD patients, it's just we don't use it at the first-tier diagnostic test anymore. So, we typically do it in selected cases after the genetic testing in those that came back inconclusive. As you know, you may run into the variant of unknown significance. You may use the muscle biopsy to see, is there any histopathology or abnormal protein Western blot that may further support the heterogenicity of the VUS. So, we still do it, but it typically comes after genetic testing and only in the selected cases that have inconclusive results or negative genetic testing. Dr Smith: I'd like to ask a question regarding serologic testing for autoantibodies. I refer to a really great case in your article. There are several of them, but this is a patient, a FKRP patient, who was originally thought to have dermatomyositis based on a low-titer ME2 antibody. You guys figured out the correct diagnosis. We send a lot of antibody panels out. Wonder if you have any wisdom, pearls, pitfalls, for how to interpret antibody tests in patients with chronic myopathies? We send a lot of them. And that's the sort of population where we need to be thinking about limb-girdle muscular dystrophies. It's a great case for those, which I hope is everyone who read your article in detail. What do you have to say about that? Dr Liewluck: Yes, so myositis antibodies, we already revolutionized a few of muscle diseases. I recall when I finished my fellowship thirteen years ago, so we don't really have much muscle myositis antibodies to check. But now the panel is expanded. But again, the antibodies alone cannot lead to diagnosis. You need to go back to your clinical. You need to make sure the clinical antibodies findings are matched. For example, if the key that- if the myocytes specific antibodies present only at the low positive title, it's more often to be false positive. So, you need to look carefully back in the patient, the group of phenotypes, and when in doubt we need to do muscle biopsies. Now on the opposite end, the other group of the antibody is the one for necrotizing autoimmune myopathy; or, the other name, immune-mediated necrotizing myopathy. This is the new group that we have learned only just recently that some patients may present as a typical presentation. I mean, when even thinking about the whole testing autoimmune myopathy, we think about those that present with some acute rapidly progressive weakness, maybe has history of sudden exposures. But we have some patients that present with very slowly progressive weakness like muscular dystrophies. So now in my practice, if I encounter a patient I suspect LGMD, in addition to doing genetic testing for LGMD, I also test for necrotizing doing with myopathy antibodies at the same time. And we typically get antibody back within what, a week or two, but projected testing would take a few months. Dr Smith: Yeah. And I guess maybe you could talk a little bit about pitfalls and interpretation of genetic tests, right? I think you have another case in your article, and I've certainly seen this, where a patient is misdiagnosed as having a genetic myopathy, LGMD, based on, let's say, just a misinterpretation of the genetic testing, right? So, I think we need to think of it on both sides. And I like the fact that the clinical aspects of diagnosis really are first and foremost most important. But maybe you can talk about wisdom in terms of interpretation of the genetic panel?  Dr Liewluck:Yes. So genetic testing, I think, is a complex issue, particularly for interpretation. And if you're not familiar with this, it's probably best to have your colleagues in genetics that help looking at this together. So, I think the common scenario we encounter is that in those dystrophies that are autosomal recessive, so we expect that the patient needs to have two abnormal copies of the genes to cause the disease. And if patients have only one abnormal copy, they are just a carrier. And commonly we see patients refer to us as much as dystrophy is by having only one abnormal copy. If they are a carrier, they should not have the weakness from that gene abnormality. So, this would be the principle that we really need to adhere. And if you run into those cases, then maybe you need to broaden your differential diagnosis. Dr Smith: I want to go back to the clinical phenomenology, and I've got a admission to make to you, Teerin. And I find it really hard to keep track of these disorders at, you know, thirty-four and climbing a lot of overlap, and it's hard to remember them. And I'm glad that I'm now going to have a Continuum article I can go to and look at the really great tables to sort things out. I'm curious whether you have all these top of mind? Do you have to look at the table too? And how should people who are seeing these patients organize their thoughts about it? I mean, is it important that you memorize all thirty-four plus disorders? How can you group them? What's your overall approach to that? Dr Liewluck: I need to admit that I've not memorize all twenty-four different subtypes, but I think what I triy to do even in my real-life practice is group it all together if you can. For example, I think that the biggest group of these LGMD is what we call alpha-dystroglycanopathies. So, this include already ten different subtypes of recessive LGMD. So alpha-dystroglycan is the core of the dystrophin-associated glycoprotein complex. And it's heavy glycosylated protein. So, the effect in ten different genes can affect the glycosylation or the process of adding sugar chain to this alpha-dystroglycan. And they have similar features in terms of the phenotype. They present with proximal weakness, calf pseudohypertrophy, very high CK, some may have recurrent rhabdomyolysis, and cardiac and rhythmic involvement are very common. This is one major group. Now the second group is the limb-girdle muscular dystrophy due to defective membrane repair, which includes two subtypes is the different and on dopamine five. The common feature in this group is that the weakness can be asymmetric and despite proximal weakness, they can have calf atrophy. On muscle biopsy sometimes you can see a myeloid on the muscle tissues. And the third group is the sarcoglycanopathy, which includes four different subtypes, and the presentation can look like we share. For the rest, sometimes go back to the table. Dr Smith: Thank you for that. And it prompts another question that I always wonder about. Do you have any theories about why such variability in the muscle groups that are involved? I mean, you just brought up dystroglycanopathy, for instance, as something that can cause a very distal predominant myopathy; others do not. Do we at this point now have an understanding given the better genetics that we have on this and work going on in therapeutic development, which I want to get to in a minute, that provides any insight why certain muscle groups are more affected? Dr Liewluck: Very good question, Gordon. And I would say the first question that led me interested in muscle disease---and this happened probably back in 2000 when I just finished medical school---is why, why, why? Why does muscle disease tend to affect proximal muscles? I thought by now, twenty-five years later, we'd have the answer. I don't. I think this, you don't know clearly why muscle diseases, some affect proximal, some affect distal. But the hypothesis is, and probably my personal hypothesis is, that maybe certain proteins may express more in certain muscles and that may affect different phenotypes. But, I mean, dysferlin has very good examples that can confuse us because some patients present with distal weakness, some patients present with proximal weakness, that's by the same gene defect. And in this patient, when we look at the MRI in detail, actually the patterns of fatty replacements in muscle are the same. Even patient who present clinically as a proximal or distal weakness, the imaging studies show the same finding. Bottom line, we don't know. Dr Smith: Yeah, who knew it could be so complex? Teerin, you brought up a really great point that I wanted to ask about, which is muscle MRI scan, right? We're now seeing studies that are doing very broad MR imaging. Do you use some muscle MRI very frequently in your clinical evaluation of these patients? And if so, how? Dr Liewluck: Maybe I don't use it as much as I could, but the most common scenario I use in this setting is when I have the genetic testing come back with the VUS. So, we look at each VUS, each gene in detail. And if anything is suspicious, what I do typically go back to the literature to see if that gene defect in particular has any common pattern of muscle involvement on the MRI. And if there is, I use MRI as one of the two to try to see if I can escalate the pathogenicity of that VUS. Dr Smith: And a VUS is a “Variant of Unknown Significance,” for our listeners. I'm proud that I remember that as a geneticist. These are exciting times in neurology in general, but particularly in an inherited muscle disease. And we're seeing a lot of therapeutic development, a lot going on in Duchenne now. What's the latest in terms of disease-modifying therapeutics and gene therapies in LGMD? Dr Liewluck: Yes. So, there are several precritical and early-phase critical trials for gene therapy for the common lymphoma of muscular dystrophies. For example, the sarcoglycanopathies, and they also have some biochemical therapy that arepossible for the LGMD to FKRP. But there are many things that I expect probably will come into the picture broader or later phase of critical tryouts, and hopefully we have something to offer for the patients similar to patients with Duchenne muscular dystrophy. Dr Smith: What haven't we talked about, I mean, holy cow? There's so much in your article. What's one thing we haven't talked about that our listeners need to hear? Dr Liewluck: Good questions. So, I think we covered all, but often we get patients with proximal weakness and high CK, and they all got labeled as having limb-girdlemuscular dystrophy. What I want to stress is that proximal weakness and high CK is a common feature for muscle diseases, so they need to think broad, need to think about all possibilities. Particularly don't want to miss something treatable. Chronic, slowly progressive cause, as I mentioned earlier, we think more about muscle dystrophy, but at the cranial range, we know that rare patients with necrotic autonomyopathy and present with limb good of weakness at a slowly progressive cost. So, make sure you think about these two when suspecting that LGMD patient diabetic testing has come back inconclusive. Dr Smith: Well, that's very helpful. And fortunately, there's several other articles in this issue of Continuum that help people think through this issue more broadly. Teerin, you certainly don't disappoint. I enjoyed listening to you about a month ago, and I enjoyed reading your article a great deal and enjoy talking to you even more. Thank you very much. Dr Liewluck: Thank you very much, Gordon. Dr Smith: Again, today I've been interviewing Dr Teerin Liewluck about his article on limb-girdle muscular dystrophy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Please be sure to check out Continuum Audio episodes for this and other issues. And thanks to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

In this episode of The Biollywood Podcast, the Executive Director of the Bipartisan Commission on Biodefense, Dr. Asha M. George, Research Principal, J.T. O'Brien, and Policy Principal Robert Bradley, discuss the 1998 episode of The X Files titled, The Pine Bluff Variant (S05E18). Premise: In The Pine Bluff Variant, FBI agent Fox Mulder goes undercover to infiltrate a domestic terrorist group suspected of possessing a genetically engineered biological weapon. As the plot unfolds, it becomes clear that the group plans to release the agent in a public space, and that the U.S. government may not only be complicit but potentially the original creator of the pathogen. The episode's title references Pine Bluff Arsenal, a real U.S. Army facility long associated with chemical and biological weapons research and destruction, anchoring the story in real-world biodefense history. Learn more about the Bipartisan Commission on Biodefense here. Follow us on X (@Biodefensecomm), LinkedIn, and Facebook for more updates. Email us with recommendations on what to review next: biollywood@biodefensecommission.org 

Claude 4.5 says: “Is Your Government Spying on You RIGHT NOW? The Shocking Truth About Federal Power, Surveillance, and Taylor Swift's 4 Million Album Sales! Hold onto your headphones, because Randumb Thoughts Episode 340 is the most explosive hour of truth you'll hear this week! Host Darren O'Neill pulls back the curtain on Operation Arctic … Continue reading "Episode #340 – Variant Venom – Randumb Thoughts Podcast"

Notes and Links to Anthony Gedell's Work       ANTHONY GEDELL writes from New Jersey publishing in Hobart, Poverty House, Variant, Revolution John, Punk Noir Magazine, and Bull. His debut novel, Love Lies in the Throes of Rhetoric, was released in October 2024. Buy Love Lies in the Throes of Rhetoric   Anthony's Instagram   Anthony's Writing for Hobart Pulp   Video Review for Love Lies in the Throes of Rhetoric   At about 1:40, Pete and Anthony talk about inspirations for the podcast At about 3:00, Anthony talks about how teaching informs his writing, and vice versa, with observations on  At about 5:20, Anthony talks about being a concerted listener and always being cognizant of “getting into the room” of wonderful writers and writing conversations At about Anthony talks about the ways in which he and the book's significance have evolved in the year since publication   At about 8:40, Anthony talks about ideas of “writing from comfortability" and  At about 9:40, Anthony responds to Pete's question about what texts have resonated with his students, which includes a major shout out for Eli Cranor At about 13:00, Anthony highlights Of Mice and Men as one example of “high intensity emotion” that moves/interests readers  At about 14:50, Anthony cites Marlon James saying that “the new American novel is the crime novel” and talks about the “writer as journalist” in discussing ideas of writing dystopian in a dystopian world and “writing towards genre”  At about 20:10, Pete and Anthony discuss ideas of the continuity of writers and writing over the centuries  At about 25:00, Anthony expands on ideas of nihilism in contemporary society  At about 31:00, Pete reads the Ecclesiastes, Ch 9, Verse 4, the introduction for Love Lies in the Throes of Rhetoric At about 32:20, Anthony responds to Pete's questions about the book's opening and significance for the rest of the book At about 35:00, Anthony talks about lessons and questions brought out in Biblical passages At about 36:00, Pete responds to Anthony's questions about how Anthony's novel is evocative of Catholic/catholic themes At about 39:30, Anthony shares moving connections in real-life and in the novel and ideas of misery and tragedy and compassion  At about 43:40, the two discuss the “snare” trope and how Eudora has been seen in two ways by a lot of readers, and Anthony shouts out Light Years by James Salter-its beautiful sentences and the possibility of Nedra in Salter's book as a “snare character” At about 48:50, The two connect meaningful scenes and quotes from the novel to memorable Scripture At about 49:50, Anthony responds to Pete's musings about the interesting “too young to feel this old” after Pete rambles about a writing project that “got away” At about 52:40, Anthony references Conrad in talking about nihilism and hopelessness, particularly with regard to Trasc and Eudora, the book's protagonists  At about 55:25, Pete compliments Anthony's use of “snappy dialogue” and asks Anthony about ideas of impotence, especially as seen with Trasc and Eudora At about 1:00:15, Anthony details particular scenes and reflects on some meanings that come from the portraits of masculinity  At about 1:04:30, Trasc and his sensitive nature is discussed, and Anthony talks about   At about 1:06:30, Anthony talks cryptically and profoundly on the writing process for his novel and quotes a memorable line from Salter's Light Years At about 1:09:30, Pete and Anthony stan Who's Afraid of Virginia Wolff? and talk about the play's “dialectical violence”   At about 1:12:00, Anthony reflects on his writing style and the place from which he writes and how boredom and “soccer dad” literature enervates  At about 1:14:50, a quote from the novel leads to the two dissecting David Foster Wallace's work and its significance, and some texts that are thought to be overly celebrated   At about 1:18:00, Anthony reflects on dystopia, worldbuilding, and “collective human behaviors” and how the physical atmosphere he creates can shadow feelings and characters' characteristics  At about 1:23:00, Anthony emphasizes the intentionality of the writing in the novel,  while at the same time allowing for the speculation that comes with the uncertain world and readers' experiences At about 1:24:40, the two reflect on Biblical connections to revelation and Revelation and dystopia and apocalypse  At about 1:26:40, Anthony responds to Pete's question about “The Court” and connection the Greek Chorus      You can now subscribe to the podcast on Apple Podcasts, and leave me a five-star review. You can also ask for the podcast by name using Alexa, and find the pod on Stitcher, Spotify, and on Amazon Music. Follow Pete on IG, where he is @chillsatwillpodcast, or on Twitter, where he is @chillsatwillpo1. You can watch other episodes on YouTube-watch and subscribe to The Chills at Will Podcast Channel. Please subscribe to both the YouTube Channel and the podcast while you're checking out this episode.       Pete is very excited to have one or two podcast episodes per month featured on the website of Chicago Review of Books. The audio will be posted, along with a written interview culled from the audio. His conversation with Hannah Pittard, a recent guest, is up at Chicago Review.     Sign up now for The Chills at Will Podcast Patreon: it can be found at patreon.com/chillsatwillpodcastpeterriehl      Check out the page that describes the benefits of a Patreon membership, including cool swag and bonus episodes. Thanks in advance for supporting Pete's one-man show, DIY podcast and extensive reading, research, editing, and promoting to keep this independent podcast pumping out high-quality content!    This month's Patreon bonus episode features an exploration of flawed characters, protagonists who are too real in their actions, and horror and noir as being where so much good and realistic writing takes place.    Pete has added a $1 a month tier for “Well-Wishers” and Cheerleaders of the Show.     This is a passion project, a DIY operation, and Pete would love for your help in promoting what he's convinced is a unique and spirited look at an often-ignored art form.    The intro song for The Chills at Will Podcast is “Wind Down” (Instrumental Version), and the other song played on this episode was “Hoops” (Instrumental)” by Matt Weidauer, and both songs are used through ArchesAudio.com.     Please tune in for Episode 304 with Erin Somers, a writer, reporter, and book critic based in the Hudson Valley. Her fiction, essays, and criticism have appeared in The New York Times Magazine, Esquire, Best American Short Stories, and elsewhere.      Her second novel, The Ten Year Affair, was named a most anticipated book by The New York Times, The Washington Post, Vulture, Bustle, LitHub, W Magazine, Orion, and Our Culture, and it will be published by Simon & Schuster on October 21, the date the episode airs.    Please go to ceasefiretoday.org, and/or https://act.uscpr.org/a/letaidin to call your congresspeople and demand an end to the forced famine and destruction of Gaza and the Gazan people.

Dave, Charlotte, and Zack have a very chaotic series of conversations about whatever this week. Want Avatar talk? It’s here! Want 25 minutes of Dave silently listening to Charlotte and Zack talk about D&D podcasts? You got it! Up Next: My Marvelous Year — 2012 pt. 6 Fantastic Four / FF #605-606 / 17-18 … […] The post My Marvelous Year 2012 Variant C: DC Movies/TV, the end of the Ultimate line, and our favorite RPG podcasts! appeared first on Comic Book Herald.

Drake Hicks, Head of Impact Investing at Variant Investments, discusses the unusual intersection of closed-end funds with impact investing, which goes beyond ESG (environmental, social and government principles) to invest in projects which have a purpose beyond just a profit margin. The firm runs the Variant Impact Fund, a high-yield closed-end interval fund whose assets are aligned with the United Nations' sustainable development goals, and Hicks talks about how shareholders benefit from the interval structure.

This week's Espresso covers news from CredAluga, Takenos, Grupalia MetaBIX Biotech and more!Outline of this episode:[00:30] – Lastro raises $16M Series A led by Prosus Ventures[00:40] – CredAluga raises $11M in Series A round led by Provence Partners[00:49] – Zippi secures $15.9M to expand credit access for Brazilian small businesses[00:59] – WorkAI secures $1M investment from M2 Digital[01:07] – Takenos raises $5M seed round co-led by Variant and Lattice[01:18] – Grupalia raises $4.8M seed round[01:30] – MetaBIX Biotech raises over $1MResources & people mentioned:Startups: Lastro, CredAluga, Zippi, WorkAI, Takenos, Grupalia, MetaBIX BiotechVCs: Prosus Ventures, Provence Partners, Itaú, Verde Asset, M2 Digital, Variant, Lattice,

durée : 00:07:34 - L'invité de 6h20 - par : Mathilde MUNOS - Alors qu'une nouvelle vague de Covid se confirme, la prochaine campagne de vaccination n'a pas encore commencé. Anne-Claude Crémieux, infectiologue à l'hôpital Saint-Louis à Paris et présidente de la commission technique des vaccinations de la Haute Autorité de Santé, est notre invitée à 6h20. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

https://youtube.com/live/ldr1BchKbsM

"Frankenstein": un nouveau variant du Covid Les brèves du jour Intelligence artificielle: décoder le langage animal La momification élaborée et la momification naturelle Le yoga du visage, est-ce que ça marche?

Ecoutez Ça va beaucoup mieux avec Jimmy Mohamed du 29 septembre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

What are the early signs of cardiac amyloidosis? Dr Alexander reviews the disproportionate burden of disease, early signs, and treatment options. Credit available for this activity expires: 9/24/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/recognizing-and-managing-variant-attr-amyloidosis-focus-2025a1000p21?ecd=bdc_podcast_libsyn_mscpedu

Dave forces Zack to weigh in on “Video Game Difficulty Discourse” irt Silksong, and Charlotte pitches “The French Method” of comic publishing. Up Next: My Marvelous Year — 2012 pt. 4 Avengers vs. X-Men #1 to #12 Read the tie-ins IF YOU DARE Uncanny X-Men #12-14 Added by Patreon backer Justin W. AvX tie-ins Wolverine […] The post My Marvelous Year 2012 Variant B: We solve comics publishing, and talk Silksong! appeared first on Comic Book Herald.

U.S. Navy veteran Chris Tann, was diagnosed with behavioral variant frontotemporal dementia in 2019 after his wife, Debra, noticed behavioral changes and began documenting unusual incidents at home. They began learning and raising awareness about a condition that is often misunderstood. Today, he is an active member of the Black Dementia Minds support group and a participant in a long-term clinical trial at Vanderbilt University.In this conversation with Being Patient's founder Deborah Kan, the couple discuss the early signs Chris exhibited prior to his diagnosis, the behavioral changes that come with behavioral variant frontotemporal dementia, caregiving strategies, and how faith plays a central role in how Chris copes with his diagnosis. Together, they emphasize the importance of awareness, advocacy, and research participation.—-If you loved listening to this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/Follow Being Patient: Twitter: https://twitter.com/Being_Patient_Instagram: https://www.instagram.com/beingpatientvoices/Facebook: https://www.facebook.com/beingpatientalzheimersLinkedIn: https://www.linkedin.com/company/being-patientBeing Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category/video/

Today we, as a group of Active Travel Adventures listeners, walk "solo together' to complete the Portuguese Way Camino Coastal Route with the beautiful Spiritual Way Variant.  We all had the same itinerary and lodging, but we could walk our own Camino, each day deciding whether to walk with others in the ATA group, solo or with new friends met along the way. You'll learn what to expect when doing an El Camino ("The Way") to Santiago in Spain, where the relics of St. James are said to be buried under the magnificent cathedral. You'll get plenty of tips and insights about planning and doing your own Camino or long distance walking holiday. Be sure to check out the webpage to get more details.  Click here for COMPLETE SHOW NOTES  See important links for planning your adventure, photos, videos and more cool info about today's show. Get FREE Travel Planners, Checklists and Packing Lists for ATA adventures (and each month you will get an email from Kit with links to all future Travel Planners (no spam promise!).  Get the monthly newsletter here. CONTACT KIT Resources  RECOMMENDED TOUR COMPANIES ******* EMAIL ME FOR PROMO DISCOUNT CODES***** Saily Affordable eSIM Overseas Mobile Phone Plans - No need to insert a physical SIM card when you travel.  Buy just the data you need to avoid expensive roaming charges.  Use Promo Code SPECIAL5 to save 5% Travel Insurance:  Quickly and easily compare rates and policies from different companies - no need to give any identifying information unless you decide to buy!  The best way to find the right policy for your adventures.  Train For Your Adventure  Ask Becki at Trailblazer Wellness to customize an at home, online personal training program for your upcoming adventure using whatever equipment you already have!  You'll get phone consultations, instruction videos and a plan to give you the best chance of success.  Becki offers a FREE initial phone consultation to see if you are a good fit.  AND she offers ATA listeners a 10% discount! Buy Me a Beer Want to support the program?  You can always buy me a coffee or beer - thanks! Amazon Kit's Picks   Please use my Amazon link to access your Amazon account.  Even if you don't purchase any of my recommendations, I get credit for anything you DO purchase - at no additional cost to you, you'll be helping to support the show and keeping it AD FREE:) SUBSCRIBE to Active Travel Adventures (fantastic adventure destinations) Join the Active Travel Adventures Facebook Group Follow ATA on Instagram Follow ATA on Pinterest (C) Active Travel Adventures, LLC - All Rights Reserved  

Zack (king of podcasts in 2050), Charlotte, and Dave chat about Eyes of Wakanda and have another “state of the MCU/DCU” talk. Also, some Predator and Alien talk! Up Next: My Marvelous Year — 2012 pt. 3 Carnage U.S.A. #1 to #5 Zeb Wells and Clayton Crain. Cool covers? Scarlet Spider #1 to #3 I […] The post My Marvelous Year 2012 Variant A: Eyes of Wakanda review! appeared first on Comic Book Herald.

In his weekly clinical update, Dr. Griffin with Vincent Racaniello are dismayed about the recent attack on public health the firing of the director of the CDC as well as resignation of 3 others members of the agency's leadership, the continued Legionnaire's outbreak in Harlem, suspension of Ixchiq the Chikungunya virus attenuated infectious vaccine, the first US case of New World screwworm before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, association Guillian-Barré syndrome with RSV vaccination, guidelines for using RSV vaccines, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, the American College Obstetricians and Gynecologists recommendations for the COVID, RSV and influenza vaccines, FDA approval letters for Pfizer, moderna and Novagax COVID vaccines including label changes for use in those between 5 through 64 years, where to find PEMGARDA, long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode White House Says New C.D.C. Director Is Fired, but She Refuses to Leave (NY Times) CDC director refuses to leave after White House order (BBC) Legionnaires' Disease: In Harlem(NYC Health) New York City Health Department Provides Update on Community Cluster of Legionnaires' Disease in Central Harlem(NYC Health: Promoting and protecting the City's health) FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live) (FDA) Vimkunya (Bavarian Nordiac) U.S. and Panama for the control of the Screwworm pest (COPEG) Rare human case of flesh-eating parasite New World screwworm identified in US(CNN) USDA Announces Sweeping Plans to Protect the United States from New World Screwworm (USDA) HHS details New World screwworm response after human case(CIDRAP) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Measles vaccine recommendations from NYP (jpg) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score (JID) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) ENFLONSIA: novel drug approvals 2025 (FDA) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Evaluation of Guillain-Barré Syndrome (GBS) following Respiratory Syncytial Virus (RSV) Vaccination Among Adults 65 Years and Older (FDA) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Evidence to Recommendations Framework (EtR): RSV Vaccination in Adults Aged 50–59 years (CDC: National Center for Immunization and Respiratory Diseases) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Veering from CDC, ACOG recommends maternal vaccination against COVID-19 (CIDRAP) ACOG Releases Updated Maternal Immunization Guidance for COVID-19, Influenza, and RSV (American College of Obstericians and Gynecologists) COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care (American College of Obstericians and Gynecologists) Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 (Pfizer)  COMIRNATY approval letter (FDA) Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 (FEEDS) SPIKEVAX approval letter (FDA) Novavax's Nuvaxovid 2025-2026 Formula COVID-19 Vaccine Approved in the U.S (Novavax) NUVAXOVID approval letter (FDA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Paxlovid (Pfizer) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1248 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.